Heat Biologics Initiates HS-110, PD-1 Combined Checkpoint Inhibitor Tiral

(RTTNews) - Clinical stage cancer immunotherapy company Heat Biologics, Inc. (HTBX), Tuesday announced the first enrollment for its Phase 1b clinical combination trial HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab in non-small cell lung cancer. At the initial stages, the trial will enroll 18 patients.

The Checkpoint Combination trial will replace existing trial in new treatment landscape, however, timeline to registration-directed study remain unchanged

This multicenter trial will evaluating the safety and efficacy of HS-110 in combination with nivolumab in non-small cell lung cancer patients who have recorded progress in disease condition after first-line therapy.